Q4 2024 13F Holders as of 12/31/2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
132M
-
Number of holders
-
89
-
Total 13F shares, excl. options
-
127M
-
Shares change
-
+84.4M
-
Total reported value, excl. options
-
$199M
-
Value change
-
+$131M
-
Put/Call ratio
-
0.38
-
Number of buys
-
54
-
Number of sells
-
-50
-
Price
-
$1.58
Significant Holders of RAPT Therapeutics, Inc. - Common Stock (RAPT) as of Q4 2024
125 filings reported holding RAPT - RAPT Therapeutics, Inc. - Common Stock as of Q4 2024.
RAPT Therapeutics, Inc. - Common Stock (RAPT) has 89 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 127M shares
of 132M outstanding shares and own 96.1% of the company stock.
Largest 10 shareholders include Medicxi Ventures Management (Jersey) Ltd (22.4M shares), ORBIMED ADVISORS LLC (13.1M shares), TCG Crossover Management, LLC (13.1M shares), Foresite Capital Management VI LLC (12.5M shares), RTW INVESTMENTS, LP (11.8M shares), BVF INC/IL (9.24M shares), Redmile Group, LLC (6.48M shares), Deep Track Capital, LP (6.01M shares), PERCEPTIVE ADVISORS LLC (5.88M shares), and FMR LLC (5.23M shares).
This table shows the top 89 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.